PD 129603 | 99696-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: PD 129603
• 英文别名: 8-chloro-1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid；3-Quinolinecarboxylic acid, 8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-；8-chloro-1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
• CAS: 99696-22-7
• 化学式: C₁₇H₁₇ClFN₃O₃
• 分子量: 365.792
• InChiKey: UGQWPWIPFYFCFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  72.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  、 PD 129603 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 6.0h， 以68%的产率得到(E)-7-(4-(2-((allyloxy)imino)-2-(thiazol-2-yl)ethyl)piperazin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  膜活性7-噻唑肟喹诺酮类作为新型DNA结合剂，可降低基因表达并发挥有效的抗甲氧西林抗性金黄色葡萄球菌活性

  摘要：

  为了绕过喹诺酮类药物的耐药性，开发了一种新型的7-噻唑肟类喹诺酮类药物作为潜在的抗菌剂。生物学测定表明，一些构建的7-噻唑肟喹诺酮类药物具有有效的抗菌效率。乙酸甲酯肟衍生物6l的抗MRSA活性比环丙沙星高32倍，后者还具有快速的杀菌能力和对哺乳动物细胞的低毒性。7-噻唑肟喹诺酮6l和环丙沙星的组合使用能够提高抗菌效力并有效缓解细菌耐药性。初步机理探索表明，化合物6l可能破坏细胞膜并插入MRSA DNA中以与DNA促旋酶结合，从而降低gyrB和femB基因的表达。以上结果有力地表明乙酸甲酯肟衍生物6l有望抵抗MRSA感染。

  DOI：

  10.1016/j.ejmech.2021.113340
• 作为产物：
  描述：

  哌嗪 、 8-氯-1-环丙基-6,7-二氟-1,4-二氢-4-氧代-3-喹啉羧酸 以 乙腈 为溶剂， 以54%的产率得到PD 129603
  参考文献：
  名称：

  喹诺酮类抗菌剂。8-取代的喹啉-3-羧酸和1,8-萘啶-3-羧酸的合成及构效关系。

  摘要：

  一系列7,8-二取代的1-环丙基-6-氟喹啉-3-羧酸，7-取代的1-环丙基-6-氟-1,8-萘啶-3-羧酸和10-取代的9-氟吡啶并苯并恶嗪已经制备了-6-羧酸并评估了其抗菌活性。在7-位（苯并恶嗪10-位）检测的侧链包括哌嗪基（g），3-氨基吡咯烷基（a），3-（氨基甲基）吡咯烷基（b）和烷基化的3-（氨基甲基）吡咯烷基（cf）。喹诺酮环系统C-8的变异包括氢，硝基，氨基，氟和氯。8氢喹诺酮和1,8-萘啶上侧链对革兰氏阴性生物的体外活性的相对增强比cf更大，b更大，g更大。由8个取代基赋予取代的喹诺酮核的活性的顺序为：F大于Cl大于萘啶大于H大于苯并恶嗪大于NH2大于NO2。这些趋势在体内得以保留。

  DOI：

  10.1021/jm00400a016

文献信息

• [EN] RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES<br/>[FR] DERIVES DE RIFAMYCINE IMINO EFFICACES CONTRES DES MICROBES PHARMACORESISTANTS
  申请人：CUMBRE INC

  公开号：WO2005070941A1

  公开（公告）日：2005-08-04

  The present invention relates to rifamycin 3-iminomethylenyl (-CH=N-) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (-CH=N-) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(-CH=N-)衍生物，包括对耐药微生物的活性。所述的利福霉素衍生物具有一个利福霉素基团，通过亚甲基亚胺基(-CH=N-)在利福霉素基团的C-3碳上与一个连接剂共价连接，而连接剂又与DNA旋转酶和拓扑异构酶IV抑制剂家族中的奎诺酮结构或其药效团共价连接。这种创新的利福霉素是新颖的，并对利福平和环丙沙星耐药微生物表现出活性。
• C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
  申请人：Combrink Keith

  公开号：US20050256096A1

  公开（公告）日：2005-11-17

  Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert their antimicrobial activity through a dual-function mechanism and therefore exhibit reduced frequency of resistance.

  当前发明的化合物涉及具有抗微生物活性的利福霉素衍生物，包括针对耐药微生物的活性。更具体地说，当前发明的化合物涉及利福霉素的C-25氨基甲酸酯衍生物，通过氨基甲酸酯键连接到该位置的另一个功能基团或药效团。由此产生的化合物通过双重功能机制发挥其抗微生物活性，因此表现出较低的抗药性频率。
• Rifamycin derivatives effective against drug-resistant microbes
  申请人：Ma Zhenkun

  公开号：US20050261262A1

  公开（公告）日：2005-11-24

  Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

  本发明涉及具有抗微生物活性的利福霉素衍生物，包括对耐药微生物的活性。本发明的利福霉素衍生物独特地设计在于，它们具有利福霉素基团通过利福霉素基团的C-3碳与连接基团共价连接，并且连接基团进一步与治疗性基团或抗菌剂/药效团共价连接。治疗性基团可以是喹诺酮、噁唑烷酮、大环内酯、氨基糖苷、四环素核心或与抗菌剂相关的结构/药效团。
• Rifamycin imino derivatives effective against drug-resistant microbes
  申请人：Ding Z. Charles

  公开号：US20050209210A1

  公开（公告）日：2005-09-22

  The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(—CH═N—)衍生物，包括对耐药微生物的活性。所述利福霉素衍生物具有利福霉素基团通过亚甲基亚胺基(—CH═N—)与连接基团共价连接于利福霉素基团的C-3碳，并且连接基团与DNA酶解酶和拓扑异构酶IV抑制剂家族中的喹诺酮结构或其药效团共价连接。本发明的利福霉素是新颖的，并且对利福平和环丙沙星耐药微生物均有活性。
• Quinolinecarboxylic acid derivatives and process for their preparation
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP0195841A1

  公开（公告）日：1986-10-01

  Quinolinecarboxylic acid derivatives of the following formula, wherein R is hydrogen atom or methyl group; hydrates and pharmaceutically acceptable salts thereof are useful as an antibacterial agent.

  下式的喹啉羧酸衍生物、 其中 R 为氢原子或甲基；其水合物和药学上可接受的盐类可用作抗菌剂。